Stable Isotope Labeled Compounds Market by Type (Carbon 13, D, Oxygen 18, N15), Application (Research, Clinical Diagnostics, Industrial), End User (Pharmaceutical & Biopharmaceutical Companies, Academic institute), Region – Global Forecast to 2024

2020-01-14
Price :
Published : Jan-2020
No. of Pages : 135

The stable isotope labeled compounds market is projected to grow at a CAGR of 3.0% during the forecast period (2019–2024).”

The global stable isotope labeled compounds market size is projected to reach USD 312 million by 2024 from USD 269 million in 2019, at a CAGR of 3.0%. The growth of this market is driven majorly by factors such as the increase in research activities in the pharmaceutical and biotechnology sector, rising proteomics research, and the rising prevalence of cancer. However, the high cost of stable isotope-labeled compounds is expected to restrain the growth of this market during the forecast period.

“By type, the H-2 labeled compounds segment is expected to grow at the highest CAGR during the forecast period.”

Based on component, the stable isotope-labeled compounds market is segmented into C-13, N-15, O-18, H-2 (deuterium), and other isotopes. The H-2 labeled compounds segment accounted for the largest market share in 2018. This segment is also expected to register the highest growth during the forecast period. This growth in this segment is driven primarily by growing drug research in the pharmaceutical industry and the increasing availability of deuterium-labeled compounds.

“By application, the research segment dominated the stable isotope labeled compounds market in 2018.”

Based on technology, the stable isotope-labeled compounds market is segmented into research, clinical diagnostics, industrial applications, and other applications. The research segment accounted for the largest share of the stable isotope-labeled compounds market in 2018, owing to rising research activities in the biomedical, pharmaceutical, environmental & ecological, and agricultural sectors.

North America stable isotope labeled compounds market is expected to witness the highest growth during the forecast period.”

The North America region market is estimated to grow at the highest CAGR during the forecast period, primarily due to the growing pharmaceutical and biopharmaceutical industry, support from the Isotope Production and Distribution Program Fund, and the presence of a large nuclear industry are driving market growth in the region.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1–21%, Tier 2–26%, and Tier 3–53%
  • By Designation: C-level–32%, Director-level–26%, and Others–42%
  • By Region: North America–34%, Europe–29%, Asia Pacific–27%,RoW-10%

The prominent players operating in the global stable isotope labeled compounds market include PerkinElmer Inc. (US), Merck KGaA (Germany), Cambridge Isotope Laboratories, Inc. (US), URENCO Limited (UK), IsoSciences, LLC (US), Medical Isotopes, Inc. (US), Omicron Biochemicals, Inc. (US), Trace Sciences International (US), Alsachim (France), Taiyo Nippon Sanso Corporation (Japan), and Rotem Industries Israel Ltd. (Israel).

Research Coverage:

The report analyzes the stable isotope labeled compounds market and aims at estimating the market size and future growth potential. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the stable isotope labeled compounds market
  • Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the stable isotope labeled compounds market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new systems, growing geographies, and recent developments in the global stable isotope labeled compounds market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and services of the leading players in the stable isotope labeled compounds market
Filed in: Pharmaceutical
Publisher : marketsandmarkets
More Reports
Title Price Buy Now

Women’s Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) – Global forecast to 2024

“Growing incidence of chronic health conditions among women and the demand in contraceptives to prevent unintended pregnancies are the key factors driving the women’s healthcare market.” The global women’s healthcare market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period. Growth in this market is mainly driven by the growing incidence of chronic health conditions among women, growing demand for contraceptives to prevent unintended pregnancies, growing focus on R&D by key players for the development of advanced products, and the government initiatives to curb population growth. On the other hand, the reluctance to use contraceptives is a major factor limiting the market growth. “Prolia is the larg......
$5650

North American Healthcare IT Market by Product (EHR, RIS, PACS, VNA, CPOE, HIE, PHM CRM, RCM, Telehealth, Healthcare Analytics, Supply Chain Management, mHealth, Fraud Analytics, Medication & Claims Management) End User (Provider,Payer) – Forecast to 2025

“North America healthcare IT market size to grow at a 16.4% CAGR” The North America healthcare IT market size is projected to reach USD 239.9 billion by 2025 from USD 96.3 billion in 2019, at a CAGR of 16.4%. There is a growing inclination across the globe towards the adoption of healthcare technologies due to the increasing need to deliver quality care to patients while curtailing escalating costs. These robust IT solutions are designed to streamline workflow in healthcare systems, reduce expenses, and facilitate compliance with stringent regulatory guidelines. “Based on products and services, the healthcare providers segment accounted for the largest share of the North America Healthcare IT market in 2018” Based on products and services, the market is segmented into heal......
$6150

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Malaysia

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Malaysia Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Malaysia". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Malaysia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Malaysia. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house ......
$1995

Multiple Sclerosis – Global Drug Forecast and Market Analysis to 2028

Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2028 Summary MS is a primary autoimmune disease with a mechanism involving recurrent inflammatory attacks on the central nervous system (CNS) due to a dysfunctional immune system, leading to neurological disability . The exact underlying cause of the inflammatory autoimmune process remains unknown; however, it is widely believed that MS results from a complex interaction of genetic susceptibility and environmental factors. MS is primarily considered an inflammatory demyelinating disorder of the CNS, and is characterized by lymphocyte and macrophage infiltrates, as well as glial cell activation. The key pathological finding in MS neural tissue is the presence of diffuse inflammatory lesions, also known as plaques, which are......
$10995

Seasonal Influenza: Epidemiology Forecast in Asia-Pacific Markets to 2028

Seasonal Influenza: Epidemiology Forecast in Asia-Pacific Markets to 2028 Summary Seasonal influenza is a contagious respiratory viral illness. There are four types of seasonal influenza viruses (A, B, C, and D); however, only types A and B cause human disease of public health concern. Influenza transmission occurs when people with flu cough, sneeze, or talk and disseminate droplets. These droplets can land in the mouths or noses of people who then inhale them into the lungs. GlobalData epidemiologists identified country-specific population-based studies published in peer-reviewed journal articles and government-collated surveillance data to build the influenza forecast, and utilized appropriate proxy data where applicable. In 2018, there were 18,518,017 cases of lab-confirmed seasonal ......
$3495

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Colombia

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Colombia Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Colombia". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the Colombia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the Colombia. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and i......
$1995

Generalized Seizures Global Clinical Trials Review, H2, 2019

Generalized Seizures Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, "Generalized Seizures Global Clinical Trials Review, H2, 2019" provides an overview of Generalized Seizures clinical trials scenario. This report provides top line data relating to the clinical trials on Generalized Seizures . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clini......
$2500

Myocardial Ischemia Global Clinical Trials Review, H2, 2019

Myocardial Ischemia Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, "Myocardial Ischemia Global Clinical Trials Review, H2, 2019" provides an overview of Myocardial Ischemia clinical trials scenario. This report provides top line data relating to the clinical trials on Myocardial Ischemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Treatment Resistant Depression Global Clinical Trials Review, H2, 2019

Treatment Resistant Depression Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, "Treatment Resistant Depression Global Clinical Trials Review, H2, 2019" provides an overview of Treatment Resistant Depression clinical trials scenario. This report provides top line data relating to the clinical trials on Treatment Resistant Depression. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's pro......
$2500

Oral Mucositis Global Clinical Trials Review, H2, 2019

Oral Mucositis Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, "Oral Mucositis Global Clinical Trials Review, H2, 2019" provides an overview of Treatment Oral Mucositis clinical trials scenario. This report provides top line data relating to the clinical trials on Oral Mucositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials data......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy